Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01315873 · ClinicalTrials.gov registry record · Phase 2
Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma
A Phase 2 study, sponsored by NYU Langone Health.
- Terminated
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT01315873 is a Phase 2 study that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 24 participants.
The verdict
NCT01315873, a Phase 2 study, was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
Patients with myeloma that has either not responded to previous treatment or has returned after previous treatment will be given a combination of the drugs bendamustine and bortezomib. The bortezomib and bendamustine will be given using an intravenous line (IV) on days 1 and 4 of each cycle, with bortezomib being given first, before each dose of bendamustine. Each cycle will be 28 days long, so patients will be treated the first week of each cycle and then have 3 weeks 'off' (without any treatment). Disease assessments will be performed on day 22 of each cycle. Patients will receive the study drugs until their disease progresses or they are withdrawn from the study. In other studies, bendamustine seems to work well with other drugs. Thus, this study hopes to show that the combination of bortezomib and bendamustine will have activity in relapsed/refractory myeloma.
Interventions
- DRUG Bendamustine
- DRUG Bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2011-09 |
| Est. Completion | 2015-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01315873
The ClinicalTrials.gov registry entry for NCT01315873 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bendamustine is the first listed.
NCT01315873 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01315873 about?
NCT01315873 is a clinical study titled "Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma". Patients with myeloma that has either not responded to previous treatment or has returned after previous treatment will be given a combination of the drugs bendamustine and bortezomib. The bortezomib and bendamustine will be given using an intravenous line (IV) on days 1 and 4 of each cycle, with b...
What is the current status of trial NCT01315873?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2011-09. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01315873?
The interventions under investigation include: Bendamustine (DRUG), Bortezomib (DRUG).
Who is sponsoring clinical trial NCT01315873?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.